Oxidized low-density lipoprotein (OxLDL) has previously been thought to promote atherogenesis through foam cell formation. However, the actual nature of OxLDL present in vivo remained obscure until recently. We have produced a monoclonal antibody, DLH3, which specifically binds to OxLDL but not to native LDL. The presence of OxLDL in the LDL fraction of human plasma was demonstrated by introducing a sandwich ELISA procedure using DLH3 together with an anti-apoB antibody. Furthermore, OxLDL levels appeared to increase in certain pathological conditions including acute myocardial infarction and carotid artery atherosclerosis. Accumulation of OxLDL in atherosclerotic lesions has also been demonstrated by immunohistochemical and biochemical studies using the DLH3 antibody. This antibody recognizes oxidized phosphatidylcholines (OxPC) generated during oxidative modification of LDL, and OxPC-apoB adducts formed in OxLDL are the presumed antigens. Measuring OxLDL in plasma would be a useful diagnostic tool for cardiovascular diseases. However, there still remain some major questions related to OxLDL, the answers to which are crucial for understanding the mechanisms of atherogenesis.
INTRODUCTION
Atherosclerosis is one of the major health concerns in developed countries. Patients with cardiovascular diseases have been increasing in number in Japan since the 1950's. It has become a major social necessity to understand the mechanism of atherogenesis and find appropriate ways of dealing with the resulting diseases.
It is also well-known that altherosclerosis is closely related to lipoprotein metabolism. In particular, oxidative modification of low-density lipoprotein (LDL) is involved in early development of atherosclerotic lesions through the formation of macrophage-derived foam cells. Foam cells, which are a typical feature of atherosclerotic lesions, appear to contain a number of foamy-shaped lipid droplets in their cytoplasm. Daniel Steinberg and his collegues first proposed that foam cells could be induced from macrophages after taking up oxidatively modified LDL (OxLDL). 1) Macrophages express receptors for OxLDL which can bind and take up OxLDL. To date, more than ten receptors for OxLDL-which are referred as scavenger receptors-have been found and cloned. [2] [3] [4] Thus it has been hypothesized that OxLDL induces foam cell formation and subsequently leads to lesion formation, although OxLDL itself was not identified in vivo until recently.
A couple of studies including ours succeeded in measuring the amounts of OxLDL in human plasma. We have developed a method to determine OxLDL in human plasma samples using a sandwich ELISA procedure with an anti-OxLDL monoclonal antibody. 5, 6) Using this method, plasma OxLDL levels were found to increase in certain pathological conditions including acute myocardial infarction and carotid artery atherosclerosis. [6] [7] [8] [9] [10] [11] Accumulation of OxLDL in atherosclerotic lesions was also demonstrated. 7, 8, 12) Now, the presence of OxLDL in human plasma is widely accepted.
Our anti-OxLDL antibody, DLH3, recognizes oxidized phosphatidylcholines (OxPC) generated during oxidative modification of LDL. 13) From the literature together with our studies, the biological and pathological features of OxPC and OxPC-apoB adducts formed in OxLDL are being recognised. [12] [13] [14] [15] [16] [17] [18] OxPC have been shown to induce monocyte-endothelial adhesion partly due to increased secretion of monocyte chemoattractant protein-1 (MCP1) from endothelial cells. 14) Recently, some subtypes of OxPC were proposed to be potent activators of PPARa 15) and PPARg. 16) The presence of cell-surface receptors for OxPC was also suggested. 17) Moreover, OxPC is directly involved in the recognition of OxLDL by the macrophage scavenger receptor CD36. [18] [19] [20] [21] In the current paper, I would like to summarize recent advances in our understanding of OxLDL biology and atherosclerosis.
ATHEROSCLEROSIS
Atherosclerosis is a pathological condition in which arteries undergo thickening of their intimal regions and lose their elasticity. However, atherosclerosis itself is rather asymptomatic, and early changes in vessel walls which lead to atheroslerotic lesions are found even in healthy young people. It is well-known that three arteries are the major sites of atherosclerosis; these are the coronary arteries, cerebral arteries and the aorta. Extensive atherosclerotic development narrows the lumen of the arteries and reduces blood flow. When the blood flow in the coronary arteries becomes completely obstructed, severe and deadly damage to cardiac muscle and heart function occurs; this is called acute myocardial infarction.
Typical anatomy of normal arteries and atherosclerotic lesions are schematically illustrated in Fig. 1 . In normal arteries, there is a layer of endothelial cells lining the luminal surface of the vessels where circulating blood comes into direct contact. A mesh-shaped sheet of elastin called elastic lamina lies between the endothelial cells and the layers of smooth muscle cells. There is accumulation of collagen fibers and lipids, and invasion of various cells including macrophages between the endothelial cells and the elastic lamina in the earliest stages of atherosclerotic lesions, which is referred as to as diffuse intimal thickening (Fig. 1b) . Fatty streaks are macroscopic lumps on the vessel walls which coalesce to form long lesions. In this stage, there is massive acculumation of lipids in intimal areas and large numbers of macrophage-derived foam cells are found. Some foam cells are generated from smooth muscle cells (Fig. 1c) . Fibrous caps are formed with smooth muscle cells and numerous fibrous proteins such as collagens are found in atheromata. In the deep regions of the atheroma, massive accumulations of macrophages, smooth muscle cells and extracellular matrix proteins are found (Fig. 1d) .
When the luminal surface of the atherosclerotic lesion is damaged or cracked, platelets immediately adhere and aggregate at the cracked sites and subsequently generate thrombi (Fig. 1e) . Thrombus formation can lead to complete occlusion of the blood vessel, and is the primary cause of myocardial and cerebral infarction. From a number of research findings it has been presumed that atheromatous lesions enriched with lipids or foam cells become vulnerable and prone to rupture.
Russel Ross proposed the so-called "modified injury-response hypothesis" as a possible mechanism of development of atheroslcerosis. 22) When endothelial cells are injured or stressed, they respond to the injury by inducing various cytokines. Then, the cytokines activate other types of cells such as macrophages, smooth muscle cells, neutrophils and others. The details of these processes remain unclear and controversial; however, the involvement of the various cells and cytokines is clear.
Stimulated endothelial cells express surface molecules and chemokines, with monocytes in the blood attaching to the endothelial cells and subsequently invading into vessel walls and differentiating into macrophages (Fig. 2) . When smooth muscle cells in the medial layer are activated by these cytokines, they de-differentiate and invade the intimal lesion from the media. These cells secrete extracellular matrix proteins such as collagens and proteoglycans. All these events combine to promote lesion formation. In early atherosclerotic lesions, a large quantity of lipid accumulates and a number of foam cells are appear in the intima. OxLDL stimulates endothelial cells to produce monocyte chemoattractant protein-1 (MCP-1) which recruits circulating monocytes into the intima. Macrophages in the intima bind and take up OxLDL, and subsequently change themselves into foam cells. Some smooth muscle cells infiltrate and move into the intimal space from the media. In advanced atheromata, a cap structure is formed with smooth muscle cells and collagens near the surface of the thickened intima, and a large number of foam cells and smooth muscle cells appear deeper in the intima. Such atherosclerotic lesions are mechanically vulnerable, and once part of the atheroma is cracked or some endothelial cells are removed, subsequent thrombus formation leads to acute myocardial infarction. The event is referred to as "plaque rupture". taken up by specific LDL receptors. 23, 24) They also found that other type(s) of receptor must be present in macrophages since chemically modified LDL was preferentially taken up not by fibroblasts but by macrophages. [24] [25] [26] Such receptors have been named "scavenger receptors".
FOAM CELLS AND OxLDL
Apart from LDL receptors, scavenger receptors are not down-regulated, hence macrophages keep taking up modified LDL and accumulate massive amounts of intracellular neutral lipid. Thus scavenger receptors were presumed to be responsible for foam cell formation. However, searching for genuine ligand(s) for the scavenger receptors has been a major undertaking. It has been demonstrated that acetylated LDL (AcLDL), prepared from LDL by treatment with acetic anhydride, is a good ligand for the macrophage scavenger receptor, although acetylation does not seem to be a physiological modification of LDL. Steinberg et al. clearly demonstrated that OxLDL is a good ligand for macrophage scavenger receptors and OxLDL can be formed in a cell-culture system, namely at 37°C without the addition of any strong chemical reagent. 1) OxLDL can be prepared by incubating LDL with low concentrations of copper ion, and remains a good ligand for the macrophage scavenger receptor. 27) Thus OxLDL is presumed to be the primary candidate for the genuine ligand of the scavenger receptor.
The first scavenger receptor was isolated, and its cDNA cloned, by Kodama et al. 28, 29) This receptor, currently called SR-A, is a trimeric glycoprotein of a 200 kDa single membrane-spanning subunit. SR-A was initially isolated using AcLDL as a ligand, however, it appeared that SR-A was able to bind with a number of agents such including OxLDL, polyinosinic acid, dextran sulfate, fucoidan, lipid A, or advanced glycated end products (AGEP). Several other receptors for OxLDL have also discovered, and to date more than ten scavenger receptors have been described [2] [3] [4] ; these are summarized in Table 1 . Involvement of SR-A or CD36 in taking up OxLDL and foam cell formation was demonstrated by over-expression of SR-A in Chinese hamster ovary cells 30) or macrophages derived from CD36-deficient patients. 31) Furthermore, there was a significant reduction of atherosclerotic lesion area in mice genetically deficient in SR-A. 32) In addition, the presence of OxLDL in atherosclerotic lesions was suggested by Witzutum and his colleagues based on immunological studies. 33, 34) Recently, new scavenger receptors have been discovered in endothelial cells. Drs. Sawamura and Kume have identified for the first time a receptor for OxLDL expressed in endothelial cells and named LOX-1.
35) Adachi, et al. found other types of receptor in endothelial cells, called SREC-I and SREC-II, which bind to acetylated LDL but not to OxLDL. 36, 37) Furthermore, Dr. Wakamiya and his colleagues cloned a novel type of collectin with a single membranespanning domain, and found that this protein, CL-P1, is a new member of the family of scavenger receptors specifically expressed in endothelial cells. 38) Since the earlier members of scavenger receptor family, SR-A, CD36 and CD68 are expressed mostly in macrophages, it is interesting that endothelial cells have different sets of receptors from those of macrophages. Recent studies have shown that LOX-1 is also expressed in arterial smooth muscle cells as well as in endothelial cells. The physiological and pathological functions of these receptors have yet to be clarified.
DETERMINATION OF OxLDL IN PLASMA
The extensive studies on macrophage scavenger receptors strongly support the hypothesis that OxLDL is the in vivo ligand responsible for foam cell formation and atherogenesis. However, quantitative and structural analysis of OxLDL present in vivo had not been performed until recently. This was due to two major obstacles: Firstly, OxLDL is a mixture of heterogeneous particles modified with various oxidation products. Secondly, the quantity of OxLDL in vivo is very small. Thus it was of vital importance to demonstrate the presence of OxLDL in plasma as well as in atherosclerotic lesions.
In an attempt to raise monoclonal antibodies against any materials specifically accumulated in human atherosclerotic lesions, we have raised a monoclonal antibody against OxLDL. 5) Mice were immunized with homogenates of human atheroma, and hybridomas were prepared by fusing myeloma cells and splenic cells from the immunized mice. Hybridomas were selected by the reactivity in the culture medium to copper-induced OxLDL on ELISA assay. Finally, we cloned a cell line, DLH3, which produced IgM antibody that binds specifically to OxLDL (Fig. 3A) .
The reactive molecules were separated on HPLC from OxLDL and oxidized phospholipids, and it was finally found that an OxPC-containing the aldehyde-group, 9CHO-PC, was one of the major molecules bound to the DLH3 antibody 13) (Fig. 3B ). DLH3 does not bind to native LDL, acetylated LDL, malondialdehyde-treated LDL (MDA-LDL), glycated LDL, or other classes of lipoproteins, because these lipoproteins are not oxidatively modified. Conversely, DLH3 binds to oxidized HDL as well as OxLDL, and even to small peptides mixed with OxPC. 6) Utilizing the DLH3 antibody, we developed a sensitive method to determine OxLDL present in human circulating plasma 6) (Fig. 4A) . To microtiter wells pre-coated with DLH3 antibody, LDL fractions separated from human plasma were added. After extensive washing, the amounts of LDL remaining in the wells were determined using antiapoB polyclonal antibody and alkaline phosphatase-conjugated second antibody. By employing a sandwich ELISA procedure, this method was able to detect selectively apoBcontaining particles modified with OxPC. Since OxLDL is a mixture of heterogeneous particles modified with various oxidation products including OxPC, the possibility remains that there might exist OxLDL particles without OxPC-apoB adducts. Thus, it is noteworthy that this method does not quantitate the absolute amounts of OxLDL, however, it is currently the most sensitive and reliable method of detecting OxLDL.
The sandwich ELISA enables us to determine the levels of OxLDL in plasma from normal subjects, and we found that the mean OxLDL concentration in normal human plasma is approximately 0.1 ng/mg LDL protein. 6) This result proves a critical issue, namely that there is a detectable amount of OxLDL in human plasma, even in healthy people. It was previously believed that OxLDL was not present in the circulation, since radio-labelled OxLDL was rapidly and almost completely cleared from the circulation within 10 min after intravenous injection into rats. 39) From our data, it can be estimated that apparently one OxLDL particle is present in every 10000 LDL particles, a very small number. It is likely that such a low concentration of OxLDL is maintained by effective clearance mechanisms.
The presence of OxLDL in the human circulation is supported by the findings from two other research groups, who also detected OxLDL in human plasma using immunological methods. [40] [41] [42] Furthermore, evidence is accumulating that OxLDL levels in human plasma are up-regulated in several disease conditions, strongly supporting the presence of OxLDL in the circulation. Currently it is widely accepted that there is a small amount of OxLDL present in human plasma. The relationship between OxLDL and disease will be discussed in the next chapter.
OxLDL AND VARIOUS DISEASES
The methods used for OxLDL determination have been applied to clinical studies. More than ten studies have demonstrated there are significant increases in OxLDL levels in patients' plasma (Table2).
6-11,42-48) Ehara, et al. showed that the OxLDL levels for patients with acute myocardial infarction were 3.4-fold higher than that of age-matched control subjects 7) (Fig. 4B) . Nishi, et al. showed that the OxLDL levels of patients with carotid atherosclerosis who underwent endarterectomy procedures were 1.5-fold higher than those of control subjects. 8) These results strongly suggest that production and accumulation of OxLDL are up-regulated in vascular diseases, and that plasma OxLDL levels could provide useful diagnostic information.
Although our sandwich method is highly sensitive, the procedure requires separation of the LDL fraction from every plasma sample, which is laborious. An easier and quicker protocol is clearly desired for clinical applications. A modified protocol has been developed and manufactured by Kyowa Medex Co. 43) In this modified protocol, plasma samples are diluted with an assay buffer prior to their being added to the microtiter wells, so that LDL separation using ultacentrifugation is not required. Using the modified protocol, Toshima et al. reported that OxLDL concentrations in patients with more than 50% coronary stenosis as shown angiographically was 1.9-fold higher than that of age-matched controls. 9) They also reported that the OxLDL concentration was a more predictable parameter than other lipid parameters such as total cholesterol, triglyceride, and HDL-cholesterol.
Another protocol for immunological detection of plasma OxLDL was developed by Holvoet et al. 41) They raised an anti-OxLDL monoclonal antibody, 4E6, with determination of OxLDL present in human plasma using a simple competitive ELISA protocol. To microtiter wells pre-coated with 4E6 antibody, were added diluted plasma samples followed by known amounts of radio-labelled OxLDL. It should be noted that the specificity of 4E6 antibody is different from that of DLH3 antibody. 4E6 binds to MDA-LDL as well as OxLDL, while DLH3 does not bind to MDA-LDL. Modification of LDL with malondialdehyde must proceed during oxidative modification of LDL as one of the modifications, as some monoclonal antibodies bind both OxLDL and MDA-LDL. 49) The epitope recognized by the 4E6 antibody has yet to be characterized.
Although both the antibody and the procedure developed by Holvoet and colleagues are significantly different from ours, they also observed significant increases in OxLDL concentrations in plasma from patients who had experienced acute coronary infarction, heart transplantation or hemodialysis. 42, 44, 45) Due to experimental differences, the actual values cannot be directly compared to each other. However, it is reasonable to believe that the various studies clearly indicate the involvement of oxidative modification of LDL in these clinical conditions.
OxLDL ACCUMULATES IN ATHEROSCLEROTIC LESIONS
According to the OxLDL hypothesis, foam cells in the lesions are generated after taking up OxLDL. Thus localization and characterization of any OxLDL present in the lesions would help to clarify the hypothesis.
Presence of OxLDL in the lesions was suggested in earlier studies using anti-OxLDL antibodies. 33, 34) These studies were performed using immunohistochemical analysis or Western blotting with single anti-OxLDL antibody at a time; therefore, these results indicate the only presence of oxidation epitope(s) but not apoB. We have performed double immunostaining studies using DLH3 antibody and anti-apoB antibody simultaneously. Co-localization of OxPC and apoB in a single macrophage-derived foam cell in early atherosclerotic lesions was observed, which is a clear demonstration of the presence of OxLDL, namely, apoB-modified with OxPC in foam cells. 6, 12) It is noteworthy that apoB is not detected outside of the foam cells in the early lesions 12) , suggesting that OxLDL is concentrated in the cells after macrophages take up OxLDL. It is well known that OxLDL is degraded in lysosomes after being taken up by macrophages. Given this, then how do the foam cells accumulate OxLDL? We measured the actual amounts of OxLDL present in J774 murine macrophages in culture using the sandwich ELISA. 12) AcLDL taken up by the macrophages disappeared completely from the cells within 4 h, whereas removal of OxLDL from the cells ceased after 4 h, with approximately 20% of OxLDL remaining in the cells even after 48 h. Cell fractionation studies revealed that the OxLDL was concentrated in lysosomal fractions, and that the lysosomal OxLDL was partially degraded. It is suggested that a portion of the modified apoB was resistant to degradation enzymes so that it remained in the lysosomes for a long time.
The amounts of OxLDL present in human atherosclerotic lesions were measured using the sandwich ELISA and the DLH3 antibody. 8) Lipoprotein fractions were separated from carotid atheromatous lesions obtained during endarterectomy. Lesion lipoprotein fractions were highly enriched with OxLDL, approximately 70 times higher than those of the plasma LDL fractions from the same patients. Furthermore, the lesion apoB is partially degraded similar to that observed in OxLDL accumulated in macrophages in culture. 8, 12) .
PLASMA OXLDL LEVELS COULD REFLECT OXI-DATION STATUS IN VIVO
As described in the last chapter, our studies together with others, have shown significant increase in plasma OxLDL levels in vascular diseases as well as hemodialysis. It is interesting to note that no conclusive evidence for increased OxLDL levels in hyperlipidemic patients has been reported so far. Even when the values are expressed as ratio of OxLDL to given amounts of LDL, we observed no differences between the hyperlipidemic patients and normolipidemic subjects.
50) It may be speculated that the lipoprotein concentration itself is not a crucial factor for LDL oxidation in vivo.
However, we found reduced plasma OxLDL levels in patients with familial lecitin : cholesterol acyltransferase (LCAT) deficiency. 48) LCAT is an enzyme which hydrolyzes the acyl moiety in PC and transfers the acyl group to free cholesterol to make cholesteryl ester. This enzyme and cholesteryl ester transfer protein (CETP) work synergistically to move cholesterol from peripheral tissues back to the liver. 51) It was unclear why OxLDL increased in the absence of LCAT based on its roles in lipoprotein metabolism, but we thought that LCAT might detoxify OxLDL to more benign forms. Radioactive OxPC was prepared by treatment of [
14 C]-PC with ferrous ion. When [ 14 C]-PC was incubated with normal plasma, radioactive CE was produced, while incubation of [ 14 C]-PC with plasma from patients with LCAT deficiency failed to produce radioactive CE. In the same experimental conditions, normal plasma, but not the LCAT-deficient plasma, produced various radioactive products from [ 14 C]-OxPC. Thus we conclude that LCAT is capable of metabolizing OxPC formed in OxLDL and contributes to the reduced plasma OxLDL levels. 52) Apart from enzymatic activities, immunological responses could also contribute to the reduced plasma OxLDL levels. For example, immunization of rabbits or mice with OxLDL has been shown to be athero-protective. 53, 54) Atheromatous lesions in apoE knockout mice increased significantly when the mice were splenectomised. 55) Furthermore, numbers of atheromatous lesions in the splenectomised-apoE knockout mice decreased dramatically when the mice were transplanted with B cells which would have been already exposed to OxLDL in aged apoE-knockout mice. Shoji et al. reported that plasma OxLDL levels correlated inversely with antiOxLDL auto-antibody titers in healthy populations. 56) It is possible that the more anti-OxLDL auto-antibody is produced, the more effectively OxLDL is cleared by immunological mechanisms, and in turn the less anti-OxLDL autoantibody is produced the more OxLDL remains in the circulation.
The major contributor to OxLDL clearance should be the liver reticulo-endothelial system. Kupffer cells, resident macrophages present in sinusoidal spaces in the liver, seem to have a large capability of removing OxLDL from the circulation. 39) Kupffer cells express scavenger receptors including SR-A, 4) however, it has been suggested that the cells possess yet unidentified receptors for OxLDL. 22, 57) Kupffer cells, as well as enzymes and immunological systems work together to remove OxLDL from the circulation. Because of these functions, human plasma OxLDL levels are likely to be tightly controlled within a narrow range. When a patient has a high OxLDL level, it might represent a major change in oxidative status somewhere in the body. It is likely that the significant increases in OxLDL levels in patients with coronary or cerebral infarction could derive from ruptured atheromata. It is thought that circulating blood is not a site of LDL oxidation since serum has strong anti-oxidative abilities. Our preliminary findings showed that the high OxLDL levels in the patients with coronary or cerebral infarction tended to decrease post-treatment over the course of a week. In vascular events, atherosclerotic lesions rupture and the OxLDL accumulated in the lesions is likely to be released into the circulation.
HOW IS OXLDL GENERATED IN VIVO?
Copper-treatment is a standard method of preparing 6 Vol. 26, No. 1
Fig. 5. What is Understood and What Remains to Be Clarified
From recent work, we now believe that OxLDL is present both in the circulation as well as in atheromatous lesions. OxLDL is responsible for foam cell formation, and it is very likely that plasma OxLDL is derived from atherosclerotic lesions. Determination of plasma OxLDL levels could be a useful marker for cardiovascular diseases. Current major questions include how LDL is oxidized in vivo, and how OxLDL is recognized by macrophages. To address these issues, further clarification of the molecular biology of OxLDL is required.
OxLDL in vitro. The procedure is both simple and reproducible. However, it has been consistently questioned whether the addition of copper sulfate, even with low concentrations of copper ion, was an artificial condition for LDL modification. OxLDL present in vivo should be somewhat different from that prepared in test tubes in vitro.
Berliner, et al. found that bioactive forms of LDL can be generated under moderate experimental conditions, and so they named them "Minimally-modified LDL" (MM-LDL). They prepared MM-LDL either by storing LDL at 4°C for 6 months, dialysis of LDL in phosphate buffered saline (PBS) containing 1 mM FeSO 4 , treatment of LDL with phospholipase A 2 and lipoxygenase, or co-incubation of LDL in endothelial cells in culture.
14,58-60) MM-LDL showed strong stimulatory activity in endothelial cells, despite its only causing a slight increase in the concentrations of thiobaribituric acid-reactive substances (TBARS), which is a classical but standardized method of evaluating lipid peroxidation. When MM-LDL was added to endothelial cells in culture, a number of responses were induced, including increased monocyte-endothelial cells interactions through MCP-1 expression, tissue factor expression, P-selection expression, or activation of PPARa. 14, 15, [58] [59] [60] We prepared MM-LDL by the dialysis procedure, and compared its features with copper-oxidized LDL. As reported in the original study, MM-LDL showed a slight increase in TBARS values, however, the reactivity of the anti-OxPC antibody DLH3 to the MM-LDL was comparable to OxLDL, suggesting that MM-LDL is actually one type of OxLDL. Additionally, OxPC-containing aldehyde groups has been shown to be highly enriched with MM-LDL rather than OxLDL (Itabe et al., unpublished data) . It is possible that MM-LDL is a better mimic of in vivo OxLDL, because of its strong cellular responses.
Another candidate for in vivo OxLDL is myeloperoxidasetreated LDL (MPO-LDL). Heinecke et al., have found that there is a massive accumulation of modified amino acids, such as chlorotyrosine or nitrotyrosine, in atherosclerotic lesions. [61] [62] [63] These modifications, namely chlorination or nitration of tyrosine residues, can be catalysed by an enzyme, myeloperoxidase (MPO). MPO, an enzyme secreted from macrophages and neutrophils, is involved in bacteriocidal activity in primary immunity through the generation of a strong oxidant, hypochlorite ion. Atherosclerotic lesions are inflammatory milieu in which large numbers of macrophages and neutrophils, as well as other cells, accumulate. Recently, MPO has been found to be capable of oxidizing LDL particles, with the resulting MPO-LDL inducing foam cell formation from macrophages. 64) One particularly intriguing characteristic of MPO is its ability to induce LDL modification even in the presence of blood serum, which is thought to be a physiologically anti-oxidative atmosphere. 64) Thus it is possible that MPO secreted from inflammatory cells in atherosclerotic lesions could oxidize LDL and thereby modify various proteins in the lesions.
Immunological approaches used to detect OxLDL have so far been successful in demonstrating that OxLDL is present in vivo. However, we still do not know what the structure of OxLDL is in vivo. OxLDL is thought to be a mixture of heterogeneously modified particles. A number of studies have been carried out on the modified forms of OxLDL which are prepared by oxidizing LDL under various conditions in vitro.
However, there is little information about the OxLDL present in vivo. The next step in this investigation requires a comprehensive analysis of the heterogeneous particles which could then clarify the composition of these modified forms.
WHICH PARTS OF OXLDL DO SCAVENGER RE-CEPTORS RECOGNIZE?
Extensive studies on scavenger receptors have resulted in a major contribution to the understanding of the mechanisms of early development of atherosclerotic lesions. There is mounting evidence that OxLDL is responsible for foam cell formation via recognition by macrophage scavenger receptors. Currently, although more than ten receptors have been identified, the molecular mechanisms underlying the recognition of OxLDL by these receptors remain largely unknown.
Doi et al. clarified the binding site in SR-A for AcLDL recognition by constructing a number of site-directed mutant receptors. 65) Peptides containing as few as 15 amino acid residues have been shown to be implicated in CD36 binding to apoptotic cells. 66) However, none of the other receptors have so far revealed their binding sites. Some scavenger receptors are capable of binding multiple ligands. SR-A binds to AcLDL, OxLDL, dextran sulfate, lipid A, AGE and so on. CD36 binds to OxLDL, fatty acids, apoptotic cells, and thrombospondin. It is still unclear whether the binding site identified in SR-A and CD36 could bind all these ligands.
Conversely, it has long been debated as to which part of OxLDL is the epitope for the recognition by scavenger receptors. Hörkkö et al., demonstrated that anti-OxPC monoclonal antibodies EO6 or DLH3 competed with macrophages for OxLDL binding, suggesting that OxPC-apoB adducts could be directly involved in recognition by scavenger receptors. 18) Although this group did not show which type of scavenger receptor is OxPC-sensitive, Silverstein et al. suggested that modified lipids were needed for OxLDL recognition by CD36. 67) Very recently, Hazen and his colleagues reported that CD36 binds to a special set of OxPC molecules formed in MPO-LDL, which contain a g-hydroxy (or oxo)-a,b-unsaturated carbonyl structure at the terminal region of the an-2 acyl groups. 20) According to these observations, aldehydecontaining OxPC molecules are relatively poor ligands for CD36, which disagrees with previous studies. Aldehyde-containing OxPC molecules may be present as monomeric lipids, but could also form OxPC-apoB adducts or aldol condensation products. 19) Further investigation of the structure of OxLDL isolated from plasma or atherosclerotic lesions is needed. Again, CD36 is the only member of the scavenger receptor family whose recognition epitope has been analyzed so far. It may be speculated that the other scavenger receptors recognize different modified structures in OxLDL.
CONCLUSIONS
Our studies, together with others, have demonstrated that OxLDL is present in vivo and could be a marker for cardiovascular diseases. However, little is understood of the actual molecular biology of OxLDL because of its heterogeneous nature. Further studies of the mechanisms of atherogenesis should aim to elucidate the structural characteristics of the OxLDL present in vivo.
